Regeneron Pharmaceuticals Inc
REGN
$0.00
-1.98%
Regeneron Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing treatments for eye disease, cardiovascular disease, cancer, and inflammation. It is a leading player in the antibody therapeutics space, with a core advantage stemming from its robust marketed portfolio and a deep pipeline developed through strategic collaborations and internal research.…
REGN
Regeneron Pharmaceuticals Inc
$0.00
Related headlines
Investment Opinion: Should I buy REGN Today?
Based on a synthesis of the financial data, valuation, analyst sentiment, and market performance, the objective assessment leans toward a 'Hold' rating. The stock's strong recent run has brought it near its 52-week high, and while fundamentals are solid, the current valuation (Forward P/E 14.7, P/S 5.63) appears to fairly reflect near-term prospects. The significant outperformance may have priced in much of the positive news, leaving limited margin of safety for new capital. Investors already holding the stock may find reasons to maintain their position, but new buyers might prefer to wait for a more attractive entry point or clearer signs of reaccelerating growth.
Sign up to view all
REGN 12-Month Price Forecast
The analysis suggests a balanced risk/reward. The stock's quality is high, but its recent appreciation and moderated growth justify a neutral stance over the next 12 months. The base case of trading within its recent range is most probable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals Inc's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
11 analysts
Implied Upside
—
vs. current price
Analyst Count
11
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage for Regeneron is active, with recent ratings from major firms including 'Buy' from Guggenheim, 'Overweight' from JP Morgan and Cantor Fitzgerald, and 'Outperform' from Oppenheimer and Evercore ISI. Other firms like RBC Capital, Morgan Stanley, and Wells Fargo maintain 'Sector Perform' or 'Equal Weight' ratings. Specific consensus target price data is not available in the provided inputs.
Bulls vs Bears: REGN Investment Factors
Regeneron presents a mixed picture. Bullish factors include strong relative performance, a fortress balance sheet, and analyst optimism driven by its blockbuster drug Dupixent. However, bearish concerns center on slowing top-line growth, volatile profitability, and a valuation that appears full given the current growth trajectory.
Bullish
- Strong Market Outperformance: Stock up 28.8% in 6 months, significantly beating S&P 500 by 31.6%.
- Robust Financial Health: Low debt (D/E 0.087), strong liquidity (Current Ratio 4.13), and high gross margin (85.4%).
- Attractive Forward Valuation: Forward P/E of 14.7 suggests market is pricing in future earnings growth.
- Analyst Support: Multiple major firms rate as Buy/Overweight, citing pipeline and Dupixent growth.
Bearish
- Slowing Revenue Growth: Q4 2025 revenue grew only 2.5% YoY, indicating potential headwinds.
- Earnings Volatility: Net income margin dropped to 21.7% in Q4 from 38.9% in Q3.
- High Valuation Multiples: P/S of 5.63 and EV/EBITDA of 13.8 are elevated for a slow-growth phase.
- Near 52-Week High: Price at $772.64 is 84% of 52-week high ($821.11), limiting near-term upside.
REGN Technical Analysis
The stock has demonstrated significant strength over the past six months, rising 28.77% from a price around $600 in early October 2025 to $772.64 as of March 31, 2026. This performance has significantly outpaced the broader market, as evidenced by a 31.59% six-month relative strength figure against the S&P 500.
In the short term, the stock has been volatile but resilient. Over the last month, the price declined 1.16%, which still represents a strong relative performance of 4.09% against the S&P 500's 5.25% drop. The three-month performance shows a modest gain of 0.10%, again outperforming the market by 4.73%.
The current price of $772.64 sits in the upper portion of its 52-week range of $476.49 to $821.11, approximately 84% of the way toward its 52-week high. The stock's low beta of 0.397 indicates it has been less volatile than the overall market during this period.
Beta
0.40
0.40x market volatility
Max Drawdown
-35.1%
Largest decline past year
52-Week Range
$476-$821
Price range past year
Annual Return
+21.8%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | -4.3% |
| 3m | -1.9% | -4.0% |
| 6m | +27.0% | -2.0% |
| 1y | +21.8% | +22.2% |
| ytd | -1.9% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue growth has been positive but moderated in the most recent quarter. Q4 2025 revenue of $3.88 billion represented a 2.5% year-over-year increase. However, profitability metrics showed pressure, with the Q4 2025 net income margin at 21.7%, down from 24.2% in Q4 2024 and significantly lower than the 38.9% margin reported in Q3 2025, reflecting quarter-to-quarter volatility.
The company maintains a very strong financial position with a low debt-to-equity ratio of 0.087 and a robust current ratio of 4.13. Cash flow generation is healthy, with trailing twelve-month free cash flow of $4.08 billion, supporting shareholder returns through dividends and share repurchases.
Operational efficiency, as measured by Return on Equity (ROE), stands at 14.4%, which is a solid level. The company's gross margin remains exceptionally high at 85.4%, underscoring the premium nature of its pharmaceutical products.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. Regeneron trades at a trailing P/E of 17.9 and a forward P/E of 14.7 based on current data. The forward P/E suggests the market is pricing in expected earnings growth.
Peer comparison data for industry averages is not available in the provided inputs. Other valuation metrics include a Price-to-Sales (P/S) ratio of 5.63 and an Enterprise Value-to-EBITDA (EV/EBITDA) ratio of 13.8, which provide additional context but are secondary given the company's profitability.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Regeneron's primary risks are operational and competitive. Financially, the company is exceptionally strong with minimal debt and ample cash flow, insulating it from credit and liquidity risks. The key risks stem from its dependence on key products like Eylea and Dupixent. Eylea faces biosimilar and competitive pressure, while Dupixent's growth, though robust, is critical to offsetting other areas. The recent quarterly margin compression (net income margin down to 21.7% from 24.2% YoY) highlights execution and cost risks. Furthermore, the biotechnology sector is subject to binary clinical trial outcomes and regulatory decisions for pipeline assets, which could significantly impact the stock. Market risk is mitigated by the stock's low beta of 0.397, but sector-wide sentiment shifts and potential drug pricing pressures remain persistent overhangs.
FAQ
Key risks include: 1) Product concentration risk, as growth heavily relies on Dupixent offsetting potential declines in Eylea; 2) Earnings volatility, evidenced by the net income margin drop from 38.9% in Q3 to 21.7% in Q4 2025; 3) Pipeline execution risk, as the company's future depends on successful clinical trials; and 4) Valuation risk, as the stock trades near its 52-week high, making it susceptible to a pullback if growth disappoints.
The 12-month outlook presents a base case target range of $720 to $820, implying modest upside from the current $772.64. This assumes the company meets analyst revenue estimates near $21.2 billion and maintains its current valuation multiples. A bull case (25% probability) could see the stock retest and exceed its 52-week high of $821, driven by stronger-than-expected Dupixent sales. A bear case (15% probability) could see a pullback toward the $580-$720 range on growth or pipeline setbacks.
REGN appears fairly valued. Its trailing P/E of 17.9 is reasonable for a profitable biotech, and the forward P/E of 14.7 suggests the market expects earnings growth. However, other multiples like the P/S ratio of 5.63 and EV/EBITDA of 13.8 are not cheap, indicating the stock is not undervalued. The valuation reflects the company's quality but also its current growth rate, leaving little margin for error.
Based on current data, REGN is assessed as a 'Hold'. The stock has had a strong run, gaining 28.8% in six months and trading at 84% of its 52-week high. While its fundamentals are strong with a forward P/E of 14.7 and a robust balance sheet, the recent price appreciation and moderated revenue growth of 2.5% in Q4 suggest much of the near-term optimism may already be priced in. New investors might wait for a better entry point.
REGN is more suitable for a long-term investment horizon. Its low beta of 0.397 indicates lower volatility relative to the market, which is preferable for long-term holders. The company's strong pipeline and financial health support a multi-year growth story. For short-term traders, the stock may be less ideal as it is trading near its recent highs, suggesting limited near-term catalysts for a major breakout without significant news.